- Report
- August 2026
- 181 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- August 2026
- 461 Pages
Global
From €5232EUR$5,850USD£4,473GBP
- Report
- July 2026
- 160 Pages
Global
From €3711EUR$4,150USD£3,173GBP
- Report
- January 2026
- 190 Pages
Global
From €3170EUR$3,545USD£2,711GBP
€3523EUR$3,939USD£3,012GBP
- Report
- March 2026
- 135 Pages
Global
From €4337EUR$4,850USD£3,708GBP
- Report
- December 2025
- 200 Pages
Global
From €7110EUR$7,950USD£6,079GBP
- Report
- March 2024
- 200 Pages
Global
From €3711EUR$4,150USD£3,173GBP
- Report
- April 2023
- 85 Pages
Global
From €4248EUR$4,750USD£3,632GBP
Carglumic acid is a drug used to treat endocrine and metabolic disorders. It is a synthetic form of N-carbamoyl-L-glutamate, an intermediate in the urea cycle. Carglumic acid is used to treat N-acetylglutamate synthase (NAGS) deficiency, an inherited disorder that can cause ammonia to accumulate in the blood. It is also used to treat hyperammonemia, a condition in which the body has too much ammonia in the blood. Carglumic acid works by helping the body break down ammonia and other nitrogen-containing compounds.
Carglumic acid is available in tablet and powder form. It is usually taken once or twice a day, depending on the condition being treated. Common side effects include nausea, vomiting, and diarrhea.
The carglumic acid market is a niche market, with few companies offering the drug. Companies in the market include Orphan Europe, Orphan Technologies, and Orphan Canada. Show Less Read more